×
QQQ   291.71 (+1.01%)
AAPL   145.30 (+1.67%)
MSFT   267.42 (+0.45%)
META   168.06 (-1.01%)
GOOGL   2,318.50 (+1.18%)
AMZN   114.01 (-0.28%)
TSLA   716.71 (+3.09%)
NVDA   154.87 (+2.36%)
NIO   22.68 (+8.88%)
BABA   123.61 (+3.77%)
AMD   78.26 (+3.86%)
MU   58.04 (+1.17%)
CGC   2.64 (-0.38%)
T   21.09 (-0.19%)
GE   62.21 (+1.04%)
F   11.47 (+3.71%)
DIS   96.27 (+0.20%)
AMC   12.69 (+0.95%)
PFE   53.27 (+0.99%)
PYPL   73.35 (+0.15%)
NFLX   184.86 (+0.43%)
QQQ   291.71 (+1.01%)
AAPL   145.30 (+1.67%)
MSFT   267.42 (+0.45%)
META   168.06 (-1.01%)
GOOGL   2,318.50 (+1.18%)
AMZN   114.01 (-0.28%)
TSLA   716.71 (+3.09%)
NVDA   154.87 (+2.36%)
NIO   22.68 (+8.88%)
BABA   123.61 (+3.77%)
AMD   78.26 (+3.86%)
MU   58.04 (+1.17%)
CGC   2.64 (-0.38%)
T   21.09 (-0.19%)
GE   62.21 (+1.04%)
F   11.47 (+3.71%)
DIS   96.27 (+0.20%)
AMC   12.69 (+0.95%)
PFE   53.27 (+0.99%)
PYPL   73.35 (+0.15%)
NFLX   184.86 (+0.43%)
QQQ   291.71 (+1.01%)
AAPL   145.30 (+1.67%)
MSFT   267.42 (+0.45%)
META   168.06 (-1.01%)
GOOGL   2,318.50 (+1.18%)
AMZN   114.01 (-0.28%)
TSLA   716.71 (+3.09%)
NVDA   154.87 (+2.36%)
NIO   22.68 (+8.88%)
BABA   123.61 (+3.77%)
AMD   78.26 (+3.86%)
MU   58.04 (+1.17%)
CGC   2.64 (-0.38%)
T   21.09 (-0.19%)
GE   62.21 (+1.04%)
F   11.47 (+3.71%)
DIS   96.27 (+0.20%)
AMC   12.69 (+0.95%)
PFE   53.27 (+0.99%)
PYPL   73.35 (+0.15%)
NFLX   184.86 (+0.43%)
QQQ   291.71 (+1.01%)
AAPL   145.30 (+1.67%)
MSFT   267.42 (+0.45%)
META   168.06 (-1.01%)
GOOGL   2,318.50 (+1.18%)
AMZN   114.01 (-0.28%)
TSLA   716.71 (+3.09%)
NVDA   154.87 (+2.36%)
NIO   22.68 (+8.88%)
BABA   123.61 (+3.77%)
AMD   78.26 (+3.86%)
MU   58.04 (+1.17%)
CGC   2.64 (-0.38%)
T   21.09 (-0.19%)
GE   62.21 (+1.04%)
F   11.47 (+3.71%)
DIS   96.27 (+0.20%)
AMC   12.69 (+0.95%)
PFE   53.27 (+0.99%)
PYPL   73.35 (+0.15%)
NFLX   184.86 (+0.43%)
NASDAQ:NKTX

Nkarta Stock Forecast, Price & News

$14.00
+0.24 (+1.74%)
(As of 07/7/2022 10:01 AM ET)
Add
Compare
Today's Range
$13.88
$14.09
50-Day Range
$11.44
$19.44
52-Week Range
$7.55
$40.64
Volume
365 shs
Average Volume
740,492 shs
Market Capitalization
$462.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.67

Nkarta MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
254.8% Upside
$49.67 Price Target
Short Interest
Healthy
16.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of Nkarta in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$53 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.59) to ($2.93) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.84 out of 5 stars

Medical Sector

642nd out of 1,433 stocks

Pharmaceutical Preparations Industry

311th out of 683 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

Nkarta logo

About Nkarta (NASDAQ:NKTX) Stock

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

NKTX Stock News Headlines

Short Interest in Nkarta, Inc. (NASDAQ:NKTX) Expands By 33.2%
What Makes Nkarta, Inc. (NKTX) a New Buy Stock
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NKTX
Fax
N/A
Employees
136
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/07/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$49.67
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+254.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
7 Analysts

Profitability

Net Income
$-86,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$120,000.00
Book Value
$7.62 per share

Miscellaneous

Free Float
28,851,000
Market Cap
$462.14 million
Optionable
Not Optionable
Beta
N/A














Nkarta Frequently Asked Questions

Should I buy or sell Nkarta stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nkarta stock.
View analyst ratings for Nkarta
or view top-rated stocks.

What is Nkarta's stock price forecast for 2022?

7 Wall Street research analysts have issued twelve-month target prices for Nkarta's shares. Their NKTX stock forecasts range from $32.00 to $75.00. On average, they predict Nkarta's share price to reach $49.67 in the next twelve months. This suggests a possible upside of 254.8% from the stock's current price.
View analysts' price targets for Nkarta
or view top-rated stocks among Wall Street analysts.

How has Nkarta's stock price performed in 2022?

Nkarta's stock was trading at $15.35 at the beginning of 2022. Since then, NKTX stock has decreased by 8.8% and is now trading at $14.00.
View the best growth stocks for 2022 here
.

When is Nkarta's next earnings date?

Nkarta is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Nkarta
.

How were Nkarta's earnings last quarter?

Nkarta, Inc. (NASDAQ:NKTX) announced its quarterly earnings data on Thursday, May, 12th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.10.
View Nkarta's earnings history
.

Who are Nkarta's key executives?

Nkarta's management team includes the following people:
  • Mr. Paul J. Hastings, CEO, Pres & Director (Age 62, Pay $902.22k) (LinkedIn Profile)
  • Dr. Nadir Mahmood Ph.D., Chief Financial & Bus. Officer (Age 43, Pay $591.24k)
  • Dr. Ralph Brandenberger Ph.D., Sr. VP of Technical Operations (Age 52) (LinkedIn Profile)
  • Dr. James Trager Ph.D., Ph.D., Chief Scientific Officer (Age 58)
  • Mr. Greg Mann, VP of Public Affairs and Investor Relations
  • Dr. Alicia J. Hager, Chief Legal Officer & Corp. Sec. (Age 52)

What other stocks do shareholders of Nkarta own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Square (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG).

When did Nkarta IPO?

(NKTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities acted as the underwriters for the IPO.

What is Nkarta's stock symbol?

Nkarta trades on the NASDAQ under the ticker symbol "NKTX."

How do I buy shares of Nkarta?

Shares of NKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nkarta's stock price today?

One share of NKTX stock can currently be purchased for approximately $14.00.

How much money does Nkarta make?

Nkarta (NASDAQ:NKTX) has a market capitalization of $462.14 million and generates $120,000.00 in revenue each year. The company earns $-86,070,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.

How many employees does Nkarta have?

Nkarta employs 136 workers across the globe.

How can I contact Nkarta?

Nkarta's mailing address is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. The official website for Nkarta is www.nkartatx.com. The company can be reached via phone at 415-582-4923 or via email at gmann@nkartatx.com.

This page (NASDAQ:NKTX) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.